AR077080A1 - Compuestos de 2,3-dihidro-1h-indeno - Google Patents

Compuestos de 2,3-dihidro-1h-indeno

Info

Publication number
AR077080A1
AR077080A1 ARP100102082A ARP100102082A AR077080A1 AR 077080 A1 AR077080 A1 AR 077080A1 AR P100102082 A ARP100102082 A AR P100102082A AR P100102082 A ARP100102082 A AR P100102082A AR 077080 A1 AR077080 A1 AR 077080A1
Authority
AR
Argentina
Prior art keywords
compounds
dihidro
indeno
cycloalkyl
alkyl
Prior art date
Application number
ARP100102082A
Other languages
English (en)
Inventor
Alexander Hird
Vibha Oza
Jamel Carlos Saeh
Li Sha
Brian Aquila
Edward Hennessy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR077080A1 publication Critical patent/AR077080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos de 2,3-dihidro-1H-indeno, métodos para obtener dichos compuestos y composiciones farmacéuticas que los contienen. Los compuestos que se describen inhiben a las proteínas IAP (proteínas inhibidoras de la apoptosis) y se pueden utilizar en el tratamiento de diversos tipos de cáncer. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) donde R1 y R2 son, independientemente, H o alquilo C1-6; R3 es H o cicloalquilo C3-8; R4 es -OC-alquil C3-10-O-, -OC-alquenil C3-10-O- u -OC-alquinil C3-10-O-, R5 es H o cicloalquilo C3-8; y R6 y R7 son, independientemente, H o alquilo C1-6; o una sal del mismo.
ARP100102082A 2009-06-12 2010-06-11 Compuestos de 2,3-dihidro-1h-indeno AR077080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18659409P 2009-06-12 2009-06-12

Publications (1)

Publication Number Publication Date
AR077080A1 true AR077080A1 (es) 2011-07-27

Family

ID=42630911

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102082A AR077080A1 (es) 2009-06-12 2010-06-11 Compuestos de 2,3-dihidro-1h-indeno

Country Status (11)

Country Link
US (1) US20100317593A1 (es)
EP (1) EP2440549A1 (es)
JP (1) JP2012529482A (es)
KR (1) KR20120046162A (es)
CN (1) CN102459238A (es)
AR (1) AR077080A1 (es)
AU (1) AU2010258437A1 (es)
CA (1) CA2765150A1 (es)
TW (1) TW201103536A (es)
UY (1) UY32704A (es)
WO (1) WO2010142994A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
WO2020046941A1 (en) * 2018-08-28 2020-03-05 Arbutus Biopharma Corporation Crystalline forms of substituted dihydroindene-4-carboxamide compounds and methods of preparing and using same
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
CN113613724A (zh) 2018-11-30 2021-11-05 葛兰素史克知识产权开发有限公司 可用于hiv疗法的化合物
WO2020148447A1 (en) 2019-01-17 2020-07-23 Debiopharm International S.A. Combination product for the treatment of cancer
JPWO2021020585A1 (es) 2019-07-31 2021-02-04
BR112022005624A2 (pt) 2019-09-25 2022-07-12 Debiopharm Int Sa Regimes de dosagem para tratamento de pacientes com carcinoma de células escamosas localmente avançado
US20230056604A1 (en) 2020-01-20 2023-02-23 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2023230432A1 (en) 2022-05-23 2023-11-30 Inhibrx, Inc. Dr5 agonist and iap antagonist combination therapy

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0396964T3 (da) * 1989-04-28 1995-10-30 Sclavo Spa Pertussistoxin-mutanter, Bordetella-stammer, der er i stand til at producere sådanne mutanter, samt deres anvendelse til udvikling af antipertussis-vacciner
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US6187557B1 (en) * 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6242569B1 (en) * 1997-02-05 2001-06-05 Tularik, Inc. Regulators of apoptosis
US6162965A (en) * 1997-06-02 2000-12-19 Novartis Ag Plant transformation methods
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6162913A (en) * 1998-07-15 2000-12-19 Bristol-Myers Squibb Co. Preparation of [4S-(4α,7α,10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido[2,1 -b] [1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20080015482A (ko) 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2001266233B2 (en) 2000-07-07 2006-06-29 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
US20080199439A1 (en) * 2003-02-12 2008-08-21 Mclendon George L IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
WO2005084317A2 (en) * 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
WO2005092326A1 (en) * 2004-03-22 2005-10-06 The Regents Of The University Of Michigan Small molecule antagonists of xiap family proteins
RU2401840C2 (ru) * 2004-07-02 2010-10-20 Дженентек, Инк. Ингибиторы iap
WO2006017295A2 (en) * 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
JP5230865B2 (ja) * 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
CN103083644B (zh) * 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Iap二聚体抑制剂
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
US7772177B2 (en) * 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
RU2007147959A (ru) * 2005-06-08 2009-07-20 Новартис АГ (CH) Органические соединения
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
CA2564872C (en) * 2005-10-25 2010-12-21 Aegera Therapeutics Inc. Iap bir domain binding compounds
JP5227805B2 (ja) * 2005-12-20 2013-07-03 ノバルティス アーゲー Ｉａｐ阻害剤とタキサン７の組合せ剤
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US20090043099A1 (en) * 2006-03-17 2009-02-12 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
NZ572836A (en) * 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5228202B2 (ja) * 2006-07-24 2013-07-03 テトラロジック ファーマシューティカルズ コーポレーション 二量体ｉａｐアンタゴニスト
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
MX2009003834A (es) * 2006-10-12 2009-04-22 Novartis Ag Derivados de pirrolidina como inhibidores de iap.
KR20090083412A (ko) * 2006-11-28 2009-08-03 노파르티스 아게 급성 골수성 백혈병의 치료를 위한 ｉａｐ 억제제의 용도
US8492429B2 (en) * 2006-11-28 2013-07-23 Novartis Ag Combination of IAP inhibitors and FLT3 inhibitors
CN101595093A (zh) * 2006-12-07 2009-12-02 诺瓦提斯公司 有机化合物
ATE517873T1 (de) * 2006-12-07 2011-08-15 Novartis Ag 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
US20110008802A1 (en) * 2007-05-07 2011-01-13 Tetralogic Pharmaceuticals Corp. TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS
US20100203012A1 (en) * 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
AU2009261919A1 (en) * 2008-06-27 2009-12-30 Pharmascience Inc. Bridged secondary amines and use thereof as IAP BIR domain binding compounds
US20110177060A1 (en) * 2008-09-19 2011-07-21 Aegera Therapeutics, Inc. Iap bir domain binding compounds
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap

Also Published As

Publication number Publication date
CA2765150A1 (en) 2010-12-16
AU2010258437A1 (en) 2012-01-12
WO2010142994A1 (en) 2010-12-16
TW201103536A (en) 2011-02-01
US20100317593A1 (en) 2010-12-16
UY32704A (es) 2011-01-31
JP2012529482A (ja) 2012-11-22
KR20120046162A (ko) 2012-05-09
CN102459238A (zh) 2012-05-16
EP2440549A1 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
SV2016005229A (es) Inhibidores de syk
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY36285A (es) Compuestos que inhiben la proteína mcl-1
UY32730A (es) Inhibidores de cyp17
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
AR095097A1 (es) Compuestos de fenoxietoxi
CO2018010787A2 (es) Compuesto de griseofulvina
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
NI201600163A (es) Derivados de diheterociclo enlazado a cicloalquilo
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.

Legal Events

Date Code Title Description
FB Suspension of granting procedure